Metoprolol Succinate: Eligible patients randomized to receive long-term therapy with oral beta-blockade
Bisoprolol: Eligible patients randomized to receive long-term therapy with oral beta-blockade
Carvedilol: Eligible patients randomized to receive long-term therapy with oral beta-blockade
Nebivolol: Eligible patients randomized to receive long-term therapy with oral beta-blockade
Study summary
To determine whether long-term treatment with oral betablocker therapy after myocardial infarction in patient with no heart failure reduces the composite outcome of recurrent MI, all-cause mortality, revascularisation with percutaneous coronary intervention or coronary artery bypass graft, ischemic stroke, incident heart failure, or malignant ventricular arrhythmia including resuscitated cardiac arrest of cardiac origin.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Left ventricular ejection fraction \> 40%
* Myocardial infarction (MI) within previous two weeks
The diagnosis of acute MI must meet the Universal European Society of Cardiology (ESC) definition of MI
Exclusion Criteria:
* Clinical evidence of heart failure at the time of discharge
* Pregnancy or of child bearing age not using safe anticonception throughout the study period
* Lack of signed informed consent and expected cooperation during follow-up
* Any medical condition where beta blocker treatment is indicated according to the treating physician
Primary outcome measure(s)
A composite of all-cause mortality, recurrent MI, revascularisation with PCI or CABG, ischemic stroke, incident heart failure, or malignant ventricular arrhythmia including resuscitated cardiac arrest of cardiac origin. — Estimated follow-up min 6 months - max 6.25 years Time to the composite of all-cause mortality, recurrent MI, revascularisation with PCI or CABG, ischemic stroke, incident heart failure, or malignant ventricular arrhythmia including resuscitated cardiac arrest of cardiag origin on an intention to treat analysis. The composite outcome will be assessed through nationwide registries and adjudicated by an independent Clinical Endpoint Adjudication Committee.
Trial sites (1)
Facility
City
Region
Status
Bispebjerg Hospital, Dept. of Cardiology Y builing 67, 1.floor, Bispebjerg Bakke 23
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.